These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25942998)

  • 41. Health care decision makers' use of comparative effectiveness research: report from a series of focus groups.
    Villa L; Warholak TL; Hines LE; Taylor AM; Brown M; Hurwitz J; Brixner D; Malone DC
    J Manag Care Pharm; 2013; 19(9):745-54. PubMed ID: 24156643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. State legislation inhibiting the operation of managed care pharmacy programs increases costs.
    Masso AR; O'Hara J
    Benefits Q; 1993; 9(3):46-51. PubMed ID: 10127198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness research: Promising area of study for pharmacists.
    Clancy CM
    J Am Pharm Assoc (2003); 2010 Mar-Apr 1; 50(2):131-3. PubMed ID: 20199952
    [No Abstract]   [Full Text] [Related]  

  • 44. The FDA's regulation of health economic information.
    Neumann PJ; Claxton K; Weinstein MC
    Health Aff (Millwood); 2000; 19(5):129-37. PubMed ID: 10992660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
    Milne CP; Cohen JP; Felix A; Chakravarthy R
    Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Industry's perception of presenting pharmacoeconomic models to managed care organizations.
    Olson BM; Armstrong EP; Grizzle AJ; Nichter MA
    J Manag Care Pharm; 2003; 9(2):159-67. PubMed ID: 14613345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
    Spooner JJ; Gandhi PK; Connelly SB
    J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacists want FDA to create new intermediate drug category.
    Traynor K
    Am J Health Syst Pharm; 2008 Jan; 65(1):10-4. PubMed ID: 18159029
    [No Abstract]   [Full Text] [Related]  

  • 49. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians.
    Miller RM; Happe LE; Meyer KL; Spear RJ
    J Manag Care Pharm; 2012; 18(1):54-62. PubMed ID: 22235955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving cost-effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: role of the pharmacist.
    Johnson SG
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S19-25. PubMed ID: 19678723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Food labeling: health claims; chromium and the risk in adults of hyperglycemia and the effects of glucose intolerance--FDA. Interim final rule.
    Fed Regist; 1998 Jun; 63(119):34104-7. PubMed ID: 10180288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Food labeling: health claims; omega-3 fatty acids and the risk in adults of cardiovascular disease--FDA. Interim final rule.
    Fed Regist; 1998 Jun; 63(119):34107-10. PubMed ID: 10180289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ; Bliss SK
    Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies.
    Brixner D; Woodward TC; Seifter N; Biskupiak J; Marciniak M; Neumann P; Oderda G
    J Manag Care Spec Pharm; 2019 Feb; 25(2):164-173. PubMed ID: 30698089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Food labeling: health claims; zinc and the body's ability to fight infection and heal wounds in adults--FDA. Interim final rule.
    Fed Regist; 1998 Jun; 63(119):34112-5. PubMed ID: 10180291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk Communication and the Pharmaceutical Industry: what is the reality?
    Edwards B; Chakraborty S
    Drug Saf; 2012 Nov; 35(11):1027-40. PubMed ID: 23061779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of the compounding of positron emission tomography drugs.
    Hung JC
    Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Top Evidentiary Gaps in Managed Care Pharmacy: A Research Agenda.
    Gembarski J; Couto J; Wilson M;
    J Manag Care Spec Pharm; 2020 Apr; 26(4):375-381. PubMed ID: 32130069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FDA considers effects of managed care marketplace on drug promotional practices.
    Wechsler J
    Formulary; 1995 Dec; 30(12):840-1. PubMed ID: 10153083
    [No Abstract]   [Full Text] [Related]  

  • 60. Food labeling: health claims; garlic, reduction of serum cholesterol, and the risk of cardiovascular disease in adults--FDA. Interim final rule.
    Fed Regist; 1998 Jun; 63(119):34110-2. PubMed ID: 10180290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.